90 citations,
June 2006 in “The American Journal of Dermatopathology”
The document concludes that accurate diagnosis of different types of hair loss requires careful examination of hair and scalp tissue, considering both clinical and microscopic features.
37 citations,
August 2016 in “Clinical, Cosmetic and Investigational Dermatology”
The document concludes that better treatments for CCCA are needed and more research is required to understand its causes related to hairstyling and genetics.
The treatment for androgenetic alopecia involves using finasteride and minoxidil with intense exercise and cold exposure to boost metabolism and reduce androgenic effects, potentially leading to hair regrowth. This approach may activate biological pathways for improved hair and overall health.
Androgenetic alopecia is caused by DHT affecting hair growth. Finasteride and minoxidil are used to manage hair loss by blocking DHT and promoting hair growth.
IGFBP‐rP1 shows potential for treating androgenic alopecia by influencing hair cycle transitions. Increasing IGF-1 levels may have similar effects to Minoxidil and 5-AR inhibitors in reducing hair loss.
Minoxidil's effectiveness is limited by the need for sulfation and proper transport to hair follicles, with tretinoin potentially enhancing its effects by promoting enzyme activity and keratinocyte differentiation. Tretinoin may improve minoxidil's response by boosting the expression of necessary enzymes and transporters.
A topical solution called "Multi-Peptide Serum for Hair Density" by The Ordinary Company, which contains several ingredients that are used in alternatives to Minoxidil and was found to have better results than 5% Minoxidil in a study. People who have tried it shared their experiences with the serum as well.